Iron-containing preparation "ferral"

FIELD: medicine, veterinary science, pharmacy.

SUBSTANCE: invention relates to the iron-containing preparation "Ferral". Iron-containing preparation "Ferral" comprises iron in bivalent form - hydroxy-ferrous oxide in the concentration 2-9%. Invention provides administration of the preparation in amount practically by 10 times less as compared with administration of the known preparations that shows the sufficient effect and doesn't cause over dosing.

EFFECT: improved and valuable properties of preparation.

3 tbl, 4 ex

 

The invention relates to agriculture, in particular animal, and can be used in medicine.

Known iron-containing drug Perpos for the prevention of nutritional anaemia and method thereof, which is prepared from normal serum of pigs or cattle, in which, after purification and liberation from high molecular weight protein components by ultrafiltration injected cationic divalent iron with a concentration of 1.0±0,15% and drawdown perform electrolysis method in duct serum (see RF application No. 92006763, class a 61 K 35/24, 1992).

However, the drug has low biological activity due to low iron content.

Known iron-containing drug Ferox to prevent elementarnoi anemia and method thereof, which is prepared on the basis of Hanks solution, and after sterilizing filtration injected cationic divalent iron with a concentration of 1.0±0.15 percent of the additive of iron carry out electrolysis method, the flow of solution (see application of the Russian Federation No. 92006855, class a 61 K 33/26, 1995, prototype)

However, the drug has low biological activity due to the low iron content.

The present invention solves the problem of increasing the biological activity of the drug used in the form of iron rich feeding.

A comparison of the proposed drug with known shows that the use of iron for the treatment of nutritional (iron deficiency) anemia in farm animals is known, however, in the known preparations of iron is in the trivalent state and to translate it into easily digestible form divalent state, it is necessary to introduce into the body of an additional quantity of hydrochloric acid that affects the gastrointestinal tract and the absorption of these drugs is low (not higher than 8-12%). Iron enters the body and with the known compounds containing, for example, sulfur, which pollutes the body of animals products half-life and decay, reduces the rate of absorption of iron. Also known drugs injected into the body, usually parenterally (by injection), which can be toxic in overdose, especially when repeated his introduction, while the use of the proposed drug Ferral in the form of iron containing supplements, in which iron is in the ferrous form - hydroxide - oxide (Fe(OH)2), is the most digestible of the body is SMOM form, has not only a direct effect of the drug on the agent, but also enhances the role of the gastrointestinal tract in the body's defenses, mainly because the absorption of iron occurs in the gastrointestinal tract, as a rule, the natural quantity of hydrochloric acid the body enough for the absorption of ferrous iron, as well as the introduction of the proposed drug Ferral need in quantities almost 10 times smaller than the introduction of known drugs, then ceteris paribus is sufficient and does not cause an overdose, which corresponds to the criteria of the invention "inventive step".

Antianemic iron preparation of Ferral content 2-9% iron in the form of hydroxide - oxide Fe(OH)2daily added to feed animals with symptoms of anemia, exhaustion, impaired bowel function. After mechanical grinding in the oral cavity of the animal feed additive drug Ferral enters the stomach. In the stomach under the action of hydrochloric acid there is no chemical change of the drug, because iron ion protected by counterions, so iron unchanged enters the duodenum and thin intestine. The process of iron absorption occurs in the duodenum and the initial section of the intestine to the "saturation if the East", thus the absorption of the incoming ferrous iron is 25-30%. By removal of iron absorption is reduced. The iron that entered the cells of the intestinal mucosa, combined with protein apoferritin, resulting in a compound ferritin. The ferritin is not absorbed, but reacts with transferrin in the blood plasma, while recovering apoferritin formed paratransgenic. The transport of iron in the body is blood plasma, where it is associated with beta-globulin (paratransgenic), and is deposited in reticulohistiocytoma system, liver, spleen and bone marrow. Under the influence of iron improves the formation of cytochrome easier is the saturation of hemoglobin with oxygen, the more rapid the main redox processes due to the increase in serum iron products iron enzymes, improves hematopoiesis, followed leucopoiesis. Normal gastro-kicheche tract.

Experiments were conducted on the mink and the piglets drug Ferral, the results of which are summarized in table 1.

recovery, %
Table 1
No.The name of the farmwho checkedanimalK-in. goals
1Production company Kirov, Moscow regionVnitibpmink42394,8
2State farm "Ray", TatarstanVnitibppuppies mink39697,7
3SE East, Leningrad oblastVnitibppigs480for 95.2

Example 1.

A method of testing drug Ferral based on the ability of the animal organism to produce antibodies in response to parenteral administration of antigen (immunity). In the experiment, the bacterial mass vaccine polyvalent GOA formal-timercallback against colibacillosis (escherichiosis) piglets, on THE other 46-21-988-81 series No. 11, made 12.12.94, and series No. 8, made 10.07.95, Armavir bio.

While the aluminum hydroxide has been replaced by the drug Ferral in adequate proportions.

Vaccine manufactured according to TU, and vaccines containing the same bacterial mass, but with iron hydroxide, were tested in parallel experiments on the activity according to THE 46-21-988-81.

The test results summarized in tables 2, 3

Table 2
Batch number of the vaccineDate 1 vaccinationDate 2 vaccinationDate of introduction of the counter. strainThe survival of experimental animals
1128.12.94,9.01.95,25.01.95,PCs No. 78-100 pieces No. 141-75
experienced28.12.94,9.01.95 g25.01.95,PCs No. 78-100 pieces No. 141-100
82.08.95,14.08.95,30. 08.95,PCs No. 78-100 pieces No. 141-100
experienced2.08.95,14.08.95,30.08.95,PCs No. 78-75. PCs No. 141-100

Based on these results, we can conclude that the presence of iron hydroxide is the active substance of the drug Ferral - the vaccine does not reduce its immunogenic properties.

Example 2.

The biological activity of the drug Ferral was tested on 401 goal. mink and 396 puppies mink. The drug is given with food to the puppies in the amount of 2-9% within 9 days, an adult is 14 days. Recovery occurred in 97,7% puppies who had anemia and 94.8% in adults. While the adults were marked by high physiological condition, in particular a good appetite, almost full eating poop, h is Kai motor ability, the presence of a pronounced luster of the coat.

Example 3.

Drug Ferral in the amount of 2-9% along with food gave 480 pigs early age within 2 weeks. Fully recovered from anemia 450 pigs (95.2 percent), while in piglets was significantly reduced disease of the digestive system, 6 - 7 % improved the palatability of feed.

Example 4.

Experimental cats and dogs during the week added to food daily to cats 5-8 mg drug Ferral, dogs 10-15 mg drug Ferral. After taking the drug in dogs and cats appeared resistant gloss to hair, her weight, her appetite improved, and was observed more energetic behavior.

The use of the proposed drug Ferral allows you to use it for individual and group use in fodder production or immediately upon filing with the feeders, which improves the appetite, stimulates the secretion of digestive juices, protects from diseases colibacteriosis, salmonellosis, a disease caused by protozoa, helminths, and renders prophylactic action against a number of diseases, eliminating the need for mass use of antimicrobial agents - coccidiostatics, which in turn makes the consumption of meat products safer for humans.

Antianemic agent based on the jelly is a, characterized in that it contains iron in the ferrous form - hydroxide-oxide with a concentration of 2-9%.



 

Same patents:

FIELD: medicine, immunology.

SUBSTANCE: invention relates to anemia treatment in infants with immunodeficiency condition. Claimed method includes alternation of tonsilgon H administration in dose of 25 drops 3 times per day for 2 weeks and IRS-19 in one dose in each nasal passage 2 times per day for 2 weeks during 3 months. Course is carried out 2 times per year in spring and autumn for two years on end. In addition to abovementioned preparations 1 ml of tymogen is administered intramuscularly 2 times per week, 2 ml of 12.5 % cycloferon is administered intramuscularly 1 time per week, 2 ml of erytrostim is administered percutaneously 1 time per week during 3 months 2 times per year in spring and autumn for two years on end.

EFFECT: method for effective recovery of red blood shoot and immunodeficiency immunopoesis.

1 tbl, 1 ex

FIELD: medicine, pediatrics, hematology.

SUBSTANCE: the present innovation could be applied in treating surgical and oncological diseases in children during treating and preventing anemia of different etiology. One should introduce ceruloplasmin at daily single dosage ranged 50-200 mg depending upon child's age against 100-200 ml 0.9%-sodiumchloride solution intravenously by drops at the rate of 40-50 drops/min. Moreover, for preventing and/or treating posthemorrhagic anemia in case of surgical operations one should introduce ceruloplasmin during 2 d before surgical operation, intraoperationally, and for 2-10 d after operation. For preventing and/or treating anemia in case of purulent-septic diseases ceruloplasmin should be introduced during chemotherapeutic days during the whole period of the course conducted, for preventing and treating radiation anemia at the background of radiation therapy ceruloplasmin should be injected once weekly during the whole period of radiotherapy course, for preventing and treating toxic and radiation anemia at the background of chemoradiation therapy ceruloplasmin should be introduced once weekly on the day of chemotherapy during the whole course of chemoradiation treatment. The innovation enables to avoid inflows of erythrocytic mass and donor's blood along with shortened number of procedures on introduction of ceruloplasmin and 4-times decrease in the risk for the development of severe anemia in children due to matching peculiar mode for ceruloplasmin introduction.

EFFECT: higher efficiency of therapy and prophylaxis.

4 cl, 5 ex

FIELD: agriculture, animal husbandry, fur farming.

SUBSTANCE: invention relates to preparations used in prophylaxis and treatment of domestic and agricultural animals and for maintaining trace elements composition of fodders. The preparation allows balancing the nutrition diet for animals with the optimal ratio of trace elements providing prophylaxis of many diseases. Proposed preparation comprising complex of iron, manganese, copper, cobalt, selenium and zinc with ethylenediamine-N,N1-disuccinic acid disodium or dipotassium salt and water comprises additionally iodine in the following ratio of components: ethylenediamine-N,N1-disuccinic acid disodium or dipotassium salt, 15-25; iron (III), 1.5-5.5; manganese (II), 0.25-3.0; copper (II), 0.12-0.55; cobalt (II), from above 0.05 to 0.3; zinc (II), 0.05-1.5; selenium (IV), from above 0.03 to 0.06; iodine (I), 0.01-0.08; water, the balance.

EFFECT: improved and valuable properties of preparation.

1 cl, 4 tbl

FIELD: medicine.

SUBSTANCE: invention proposes an agent for correction of disturbances in production of cytokines and markers of activation of immune system cells in chronic iron-deficient anemia. Agent represents Sorbifer Durules known early as preparation used in treatment of iron-deficient anemia. Invention provides recovering the level of anti-inflammatory cytokines (IL-1, IL-6, IL-8, FNO-α, INF-α and INF-γ) and normalization of cellular immunity by indices of markers CD-25, CD-71 and CD-34.

EFFECT: valuable medicinal properties of agent.

2 tbl, 1 ex

FIELD: veterinary.

SUBSTANCE: agent is based on complex compound of colloidal iron liganded by polyoxymethylene-lauric alcohol and contains following components, mg: colloidal iron 50.0-60.0, lauric alcohol 0.1-0.3, copper 0.1-0.3, zinc 0.1-0.3, cobalt 0.1-0.3, selenium 0.001-0.005, and water to 1000. Agent can further contain 30.0-50.0 mg glucose and 0.1-0.6 mg polyvinyl alcohol.

EFFECT: enabled therapeutical and preventive efficiency at low toxicity, the same dispersity, and high stability upon storage.

3 tbl, 7 ex

FIELD: pharmaceutics, veterinary science.

SUBSTANCE: the present innovation deals with preventing and treating hypomicroelementosis in different farm and domestic animals, furred animals, and, also, for enhancing the growth in animals, and treating a number of specific diseases and, also, for maintaining microelemental composition of feedstuffs. The suggested preparation includes chelated complex of iron, manganese, zinc, copper, cobalt, selenium and iodine with organic ligand of complexone type and water. According to the innovation as a chelation ligand it contains trisodium salt of methionine succinic (α-amino-γ-methylthiobutyric-N-succinic) acid at a certain ratio of components. The innovation provides to obtain preparation in soluble form being capable to be well digested by the animal.

EFFECT: higher efficiency.

FIELD: medicine, pharmacology.

SUBSTANCE: invention relates to method for assay of optimized regimens in dosing erythropoietin (EOR). Invention proposes a system for election of one or some regimens in dosing by using pharmacokinetic/pharmacodynamic (PK/PD) as a model for assay of PK/PD pattern regimens. Then method involves selection of such regimen that provides the serum concentration of EOR exceeding its before administration for 5-30 days between administrations of EOR. Invention provides optimal applying EOR for correction of blood indices changes and treatment of diseases associated with them.

EFFECT: improved and valuable modeling method.

50 cl, 81 dwg, 2 tbl, 8 ex

FIELD: organic chemistry, biochemistry, medicine, pharmacy.

SUBSTANCE: invention relates to new aminobenzophenones of the formula (I):

or their pharmaceutically acceptable salts. These compounds elicit properties of inhibitors of cytokines secretion, in particular, 1β-interleukin (IL-1β) and tumor necrosis α-factor (TNF-α) and to secretion of polymorphonuclear superoxide that are useful for treatment of inflammatory diseases, for example, skin diseases, such as psoriasis, atopic dermatitis. In the formula (I) R1 is taken among the group consisting of halogen atom, hydroxy-, mercapto-group, trifluoromethyl, amino-group, (C1-C3)-alkyl, (C2-C3)-olefinic group, (C1-C3)-alkoxy-, (C1-C3)-alkylthio-, (C1-C6)-alkylamino-group, (C1-C3)-alkoxycarbonyl, cyano-group, carbamoyl, phenyl or nitro-group under condition that when R1 means a single substitute then it at ortho-position, and when R1 means more one substitute then at least one substitute of R1 is at ortho-position; R2 means one substitute at ortho-position being indicated substitute is taken among the group consisting of (C1-C3)-alkyl, (C1-C3)-alkoxy-group; R3 means hydrogen, halogen atom, hydroxy-, mercapto-group, trifluoromethyl, amino-group, (C1-C3)-alkyl, (C2-C3)-olefinic group, (C1-C3)-alkoxy-, (C1-C3)-alkylthio-, (C1-C6)-alkylamino-group, (C1-C3)-alkoxycarbonyl, phenyl, cyano-, carboxy-group or carbamoyl; R4 means hydrogen atom or (C1-C3)-alkyl; Q means a bond or -SO2-; Y means (C1-C15)-alkyl, (C3-C10)-carbocyclic group or phenyl being each of them can be substituted optionally with one or some similar or different substitutes designated by the formula R5; R5 means halogen atom, (C1-C4)-alkyl, amino-, (C1-C3)-alkoxy-group, (C1-C3)-alkoxycarbonyl or -COOH; X means oxygen or sulfur atom. Also, invention relates to a pharmaceutical composition and to a method for treatment and/or prophylaxis of inflammatory diseases.

EFFECT: valuable medicinal properties of compounds and composition.

9 cl, 2 sch, 2 tbl, 29 ex

FIELD: medicine, phthisiology, anesthesiology.

SUBSTANCE: during the day of operation one should perform autohemotransfusion, then introduce epocrine intravenously by drops at the dosage of 50-200 U/kg patient's body weight; next day after interference one should inject epocrine subcutaneously at the dosage of 25-100 U/kg; at hematocrit level being below 35% 48 h after operation it is necessary to repeat subcutaneous injection of the above-mentioned preparation at the dosage not exceeding 50 U/kg. The present innovation favors hemopoiesis stimulation in postoperational period, that, in its turn, accelerates postoperational rehabilitation in patients of this group and enables, also, to avoid allotransfusions being dangerous because of immunoconflicting reactions.

EFFECT: higher efficiency of compensation.

1 ex, 1 tbl

The invention relates to pharmaceutical industry and relates to a method of producing iron-containing drug for the treatment and prevention of iron deficiency anemia in animals by the interaction of organic acids with gemostimuliruyuschee properties, isolated from extracts of peat, with a hydroxide of iron (11), selected from water-soluble salts of iron (11) the deposition of the alkaline solution with the subsequent laundering of water impurities

FIELD: veterinary science.

SUBSTANCE: the present innovation deals with supplementing the feedstuff with mineral additive as neutralized white slime of alumina production of the following composition, weight%: aluminum oxide 25-35; silicon oxide 20-25; iron oxide 3-10; calcium oxide 3-10; sodium oxide 15-20; sulfur oxide 3-6; potassium oxide 0.5-2.0, free alkali, 0.02, not more; weight portion of moisture 15, not more, to be introduced once daily for about 5-7 d before transportation at the dosage of 200-300 g/animal/d. The innovation provides decreased level of stress and loses of meat productivity in cattle.

EFFECT: higher efficiency.

4 tbl

FIELD: agriculture, animal science.

SUBSTANCE: the present innovation deals with introducing medicinal preparation as a complex compound of ferric iron sulfate with beet sugar and zinc oxide. The remedy should be introduced intrauterinely as 2-5%-solution in distilled water at the dosage of 25-35 ml. Application of the present method enables to restore reproductive function in cows due to removing inflammatory processes in reproductive sphere along with some diseases caused by pathogenic microflora and its mixed forms and, also, liquidate prolonged groundless terms of sterility in cows.

EFFECT: higher efficiency of stimulation.

2 tbl

FIELD: medicine.

SUBSTANCE: invention proposes an agent for correction of disturbances in production of cytokines and markers of activation of immune system cells in chronic iron-deficient anemia. Agent represents Sorbifer Durules known early as preparation used in treatment of iron-deficient anemia. Invention provides recovering the level of anti-inflammatory cytokines (IL-1, IL-6, IL-8, FNO-α, INF-α and INF-γ) and normalization of cellular immunity by indices of markers CD-25, CD-71 and CD-34.

EFFECT: valuable medicinal properties of agent.

2 tbl, 1 ex

FIELD: veterinary.

SUBSTANCE: agent is based on complex compound of colloidal iron liganded by polyoxymethylene-lauric alcohol and contains following components, mg: colloidal iron 50.0-60.0, lauric alcohol 0.1-0.3, copper 0.1-0.3, zinc 0.1-0.3, cobalt 0.1-0.3, selenium 0.001-0.005, and water to 1000. Agent can further contain 30.0-50.0 mg glucose and 0.1-0.6 mg polyvinyl alcohol.

EFFECT: enabled therapeutical and preventive efficiency at low toxicity, the same dispersity, and high stability upon storage.

3 tbl, 7 ex

The invention relates to medicine, in particular tuberculosis, and can be used to limit complications and side effects in the treatment of tuberculosis

The invention relates to medicine and pharmacology, namely, clinical Hematology, and can be used for the prevention and treatment of iron deficiency anemia
The invention relates to pharmaceutical industry
The invention relates to chemical-pharmaceutical industry, namely the creation of a multivitamin preparation with mineral additives
The invention relates to veterinary medicine

The invention relates to veterinary medicine

FIELD: veterinary.

SUBSTANCE: agent is based on complex compound of colloidal iron liganded by polyoxymethylene-lauric alcohol and contains following components, mg: colloidal iron 50.0-60.0, lauric alcohol 0.1-0.3, copper 0.1-0.3, zinc 0.1-0.3, cobalt 0.1-0.3, selenium 0.001-0.005, and water to 1000. Agent can further contain 30.0-50.0 mg glucose and 0.1-0.6 mg polyvinyl alcohol.

EFFECT: enabled therapeutical and preventive efficiency at low toxicity, the same dispersity, and high stability upon storage.

3 tbl, 7 ex

Up!